Manuel Llobet, CEO at Allergy Therapeutics, stated: “We are thrilled with these extremely positive results demonstrating dose dependent efficacy of the product including the current marketed dose. This study represents
Allergy Therapeutics Plc (LON:AGY), a leading, fully-integrated commercial biotechnology company specialising in allergy vaccines, today announces that new data from a study investigating immune responses produced by microcrystalline tyrosine (MCT®)-based vaccines
Clinical development towards submission Allergy Therapeutics is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (AIT), continues to gain
Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Finance Director, will host a meeting and call for analysts to provide an update on the Group, followed by a Q&A session,
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announced that it has signed a contract with AGC Biologics (Heidelberg, Germany) to scale up the
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announced that recruitment has been completed in its grass allergy Phase II study (G205), with results
Allergy Therapeutics (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite
Growth in a tough market Allergy Therapeutics plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT), continues to
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: “Our strategy to prioritise patient friendly vaccines with focus on patient compliance and improving adherence rates is demonstrating success. Our portfolio
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics LON:AGY, commented: “The completion of recruitment in our pivotal Phase III clinical study with PQ Birch is an important milestone for the
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
